Anne Ploquin1, Stephanie Truant2, Guillaume Piessen3, Perrine Vuagnat4, Capucine Baldini4, Stephane Cattan5, Mohamed Hebbar4. 1. Department of Medical Oncology, University Hospital, Lille, France anne.ploquin@chru-lille.fr. 2. Department of Digestive Surgery and Transplantation, University Hospital, Lille, France. 3. Department of Digestive and Oncological Surgery, University Hospital, Lille, France. 4. Department of Medical Oncology, University Hospital, Lille, France. 5. Department of Hepatogastroenterology, University Hospital, Lille, France.
Abstract
BACKGROUND: Prognosis of patients with locally advanced or metastatic pancreatic adenocarcinoma is poor. In this study, we assessed the predictive value of easily available baseline factors for prolonged survival. PATIENTS AND METHODS: We conducted a retrospective study on patients who received gemcitabine between 1999 and 2010 for locally advanced or metastatic pancreatic adenocarcinoma. The primary end-point was the 12-month survival rate. RESULTS: We included 195 patients. The median age was 62.9 years; the performance status was 0-1 in 80 and 2-3 in 92 patients. The median number of metastatic sites was one. A total of 73 patients (37.4%) were alive 12 months after beginning chemotherapy. In multivariate analysis, no liver metastasis, CA19-9 level <250 IU/ml and localized or locally advanced cancer at diagnosis were good prognostic factors. According to a clinical score based on these features, overall survival was 7.7, 13.5, 19.7 and 21.0 months, respectively (p<0.001). CONCLUSION: We identified easily available prognostic factors for prolonged survival in patients treated with gemcitabine. Copyright
BACKGROUND: Prognosis of patients with locally advanced or metastatic pancreatic adenocarcinoma is poor. In this study, we assessed the predictive value of easily available baseline factors for prolonged survival. PATIENTS AND METHODS: We conducted a retrospective study on patients who received gemcitabine between 1999 and 2010 for locally advanced or metastatic pancreatic adenocarcinoma. The primary end-point was the 12-month survival rate. RESULTS: We included 195 patients. The median age was 62.9 years; the performance status was 0-1 in 80 and 2-3 in 92 patients. The median number of metastatic sites was one. A total of 73 patients (37.4%) were alive 12 months after beginning chemotherapy. In multivariate analysis, no liver metastasis, CA19-9 level <250 IU/ml and localized or locally advanced cancer at diagnosis were good prognostic factors. According to a clinical score based on these features, overall survival was 7.7, 13.5, 19.7 and 21.0 months, respectively (p<0.001). CONCLUSION: We identified easily available prognostic factors for prolonged survival in patients treated with gemcitabine. Copyright
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Kai Bachmann; Anna Neumann; Andrea Hinsch; Michael F Nentwich; Alexander T El Gammal; Yogesh Vashist; Daniel Perez; Maximilian Bockhorn; Jakob R Izbicki; Oliver Mann Journal: J Surg Oncol Date: 2014-12-02 Impact factor: 3.454
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: K Eto; H Kawakami; M Kuwatani; T Kudo; Y Abe; S Kawahata; A Takasawa; M Fukuoka; Y Matsuno; M Asaka; N Sakamoto Journal: Br J Cancer Date: 2013-03-14 Impact factor: 7.640
Authors: Justin M Lebenthal; Junting Zheng; Paul A Glare; Eileen M O'Reilly; Andrew C Yang; Andrew S Epstein Journal: Cancer Date: 2021-01-20 Impact factor: 6.860